Compare Davita Inc (DVA) vs GE Vernova Inc (GEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs GE Vernova Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while GE Vernova Inc trades at $1,010.32 (market cap $265.56B). The key difference: GE Vernova Inc is far larger — about 23.5× Davita Inc's market cap, and GE Vernova Inc pays a 0.2% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and GE Vernova Inc for 36 Days on average.
| DVA | GEV | |
|---|---|---|
Market Cap | $11.28B | $265.56B |
Volume | 650,294 | 1,805,141 |
Sector | Health | Industrials |
52-Week High | $240.96 | $1.17K |
52-Week Low | $103.87 | $547.96 |
Typical Hold Time | 113 Days | 36 Days |
Enterprise Value | $24.00B | $255.23B |
Dividend Yield | — | 0.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
GE Vernova (GEV) trades at $997.09, down 3.12% today but maintains strong analyst support with 22 buy ratings and a $1,270 consensus price target. The stock shows bullish technical signals with support at $985 and resistance at $1,005. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 missed estimates. The company benefits from AI-driven power demand growth and secured the first US construction permit for its BWRX-300 small modular reactor.
GEV presents compelling growth potential driven by AI infrastructure demand and nuclear energy expansion, with revenue projected to grow from $38.1B to $41.4B. However, elevated valuation multiples (P/E 28.59, EV/EBITDA 85.02) and execution risks in the wind power segment warrant caution. The strong analyst consensus and 45% YTD gain suggest continued momentum if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →
